Chronic Hepatitis B Market Growth Outlook Indicating Expansion To $4.73 Billion By 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Chronic Hepatitis B Market Between 2026 And 2030?

The chronic hepatitis b market size has experienced consistent expansion in recent years. It is anticipated to increase from $3.93 billion in 2025 to $4.1 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.2%. This historical growth can be attributed to enhancements in hepatitis B screening programs, wider availability of antiviral drugs, increased awareness concerning liver disease complications, greater adoption of nucleos(t)ide analogs, and the establishment of long-term disease monitoring protocols.

The chronic hepatitis b market is projected to experience consistent expansion over the upcoming years. Its value is anticipated to reach $4.74 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.7%. This projected increase during the forecast period is primarily driven by greater investments in next-generation HBV therapies, a growing need for finite-duration treatment regimens, the broadening of therapeutic vaccine development, a heightened emphasis on eradicating viral reservoirs, and more global initiatives aimed at eliminating hepatitis. Key trends identified for this period encompass the increased use of long-term antiviral treatments, the advancing development of functional cure methods, a stronger focus on early disease identification and monitoring, the broadening of immune-modulating treatment approaches, and improved patient adherence programs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

What Important Drivers Are Powering The Chronic Hepatitis B Market Growth?

The significant prevalence of chronic hepatitis B infection is anticipated to drive the expansion of the chronic hepatitis B virus market in the future. Hepatitis B, a liver infection resulting from the hepatitis B virus (HBV), can be prevented through vaccination. The rise in hepatitis B infection rates is attributed to multiple factors, particularly in low- and middle-income regions, where insufficient vaccination coverage leads to increased transmission as many individuals remain unprotected. An escalation in hepatitis B infection rates is expected to heighten the demand for diagnostic tests and treatment options. For instance, in June 2024, a report issued by the Centers for Disease Control and Prevention (CDC), a US-based government entity, indicated that increasing global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million deaths attributable to hepatitis B between 2022 and 2050. In 2022, there were 1.2 million new cases of hepatitis B virus (HBV) infection. Therefore, the high prevalence of hepatitis B infection will stimulate the chronic hepatitis B virus market.

Which Segment Groups Define The Chronic Hepatitis B Market Landscape?

The chronic hepatitis b market covered in this report is segmented –

1) By Drug Class: Antivirals, Immune Modulators

2) By Gender: Male, Female

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Antivirals: Nucleos(T) Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)

2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)

Which Trends Are Expected To Shape The Chronic Hepatitis B Market?

A primary focus for major companies operating in the chronic hepatitis B market involves technological advancements, particularly novel antiviral therapies. These innovative medications are designed to combat viral infections, including resistant strains, by hindering viral replication and utilizing advanced delivery systems, with ongoing clinical trials assessing their safety and efficacy, such as bepirovirsen for chronic hepatitis B. An illustration of this progress occurred in February 2024, when GSK plc, a UK-based multinational pharmaceutical and biotechnology company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products, was granted U.S. Food and Drug Administration (FDA) Fast Track designation for bepirovirsen. This investigational antisense oligonucleotide (ASO) aims to treat chronic hepatitis B (CHB). Bepirovirsen functions by targeting and degrading the RNA of the hepatitis B virus (HBV), potentially enabling the immune system to regain command over the infection. The drug has demonstrated encouraging outcomes in Phase IIb trials, specifically the B-Clear and B-Sure studies, where it proved effective in lowering hepatitis B surface antigen (HBsAg) levels and achieving durable viral suppression.

Which Firms Are Competing In The Chronic Hepatitis B Market?

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

Access The Complete Chronic Hepatitis B Market Report:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

What Is The Largest Regional Market In The Chronic Hepatitis B Market?

North America was the largest region in the chronic hepatitis B market in 2025. The regions covered in the chronic hepatitis b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Chronic Hepatitis B Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp

Browse Through More Reports Similar to the Global Chronic Hepatitis B Market 2026, By The Business Research Company

Chronic Disease Management Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Pain Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Care Management Software Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-care-management-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795